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“It was in this way that the gray cub learned other attributes of his mother than the
soft, soothing tongue. In his insistent crawling toward the light, he discovered in her
a nose that with a sharp nudge administered rebuke, and later, a paw, that crushed
him down or rolled him over and over with swift, calculating stroke. Thus he
learned hurt; and on top of it he learned to avoid hurt, first, by not incurring the risk
of it; and second, when he had incurred the risk, by dodging and by retreating.
These were conscious actions, and were the results of his first generalizations upon
the world. Before that he had recoiled automatically from hurt, as he had crawled
automatically toward the light. After that he recoiled from hurt because






Despite extensive research on the mechanisms of nociceptive pain, little is known
about the processes that lead to neuropathic pain development. As one of the most
severe and drug-resistant forms of chronic pain, neuropathic pain represents a
major burden for patients, their families, and society. Therefore, new insights into
the pathophysiology of neuropathic pain are needed.
The amygdala represents a complex of brain nuclei responsible for mediating
negative emotions, such as fear. Moreover, maladaptive changes in the amygdala
contribute to the development of chronic pain and its comorbidities, such as
anxiety and depression. However, little is known about the mechanisms for
amygdala-mediated pain hypersensitivity in neuropathy. We therefore investigated
descending pathways engaged by the amygdala for modulation of spinal
nociception in neuropathic rats.
In particular, we investigated the contribution of oxidative stress in the amygdala
on the development of neuropathic pain. Oxidative stress is characterized by
overproduction and poor detoxification of reactive oxygen species (ROS). ROS act as
endogenous agonists of transient receptor potential (TRP) channels, which account
for transduction of noxious stimulation to a nociceptive signal in peripheral nerves
and for nociceptive transmission in the spinal cord. We therefore assessed how
blocking TRP channels and detoxification of ROS with antioxidants in the amygdala
influence pain hypersensitivity and pain affect in neuropathic rats.
Furthermore, we investigated whether electrical cortical stimulation can reverse
changes associated with pronociceptive activity of the amygdala. In particular, we
examined descending pathways recruited by stimulation of the secondary
somatosensory cortex (S2), which has proven to be an efficacious site for
attenuation of drug-resistant neuropathic pain by transcranial magnetic stimulation
(TMS) in patients.
In the present series of studies, we demonstrate that N-methyl-D-aspartate
(NMDA), TRPA1,  and  TRPC4/5 channels in the amygdala contribute to the
development of neuropathic pain and that amygdaloid treatment with antioxidants
can attenuate this pain. Furthermore, we provide evidence that S2 stimulation
suppresses spinal nociception in neuropathic animals with hypersensitivity, but not
in animals without hypersensitivity or in control animals. Medullospinal
serotonergic pathways acting on the spinal 5-HT1A receptor underlie the descending
pain inhibition in neuropathic animals both following treatment of the amygdala
with antioxidants or TRPA1 antagonists and following S2 cortex stimulation.
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POPULAR ABSTRACT IN FINNISH
Hermovauriokipu: mantelitumakkeen hapetusstressi
aiheuttajana ja aivokuoren stimulaatio hoitokeinona
Vaikka kivun fysiologisia mekanismeja on tutkittu runsaasti, niin hermovaurion
aiheuttaman neuropaattisen kivun ja kivulle herkistymisen mekanismit ovat vielä
monilta osin tuntemattomia. Hermovauriokipu on usein kroonista eli pitkäkestoista
ja nykyisin käytössä olevat hoitomuodot tehoavat hermovauriokipuun usein
huonosti. Yleisyytensä ja vaikeahoitoisuutensa vuoksi krooninen hermovauriokipu
on merkittävä hyvinvointia heikentävä tekijä yhteiskunnassa. Siksi onkin tarpeen
saada lisätietoa hermovauriokivun patofysiologisista mekanismeista, joiden
parempi tuntemus voi auttaa kehittämään tehokkaampia hoitomuotoja.
Mantelitumake on keskeinen aivorakenne negatiivisille emootioille kuten pelolle.
Patofysiologisissa tiloissa syntyvien mantelitumakkeen rakenteellisten ja
toiminnallisten muutosten tiedetään myötävaikuttavan kroonisten kiputilojen sekä
niihin liittyvien emotionaalisten häiriötilojen kuten ahdistuksen ja pelon syntyyn.
Mekanismit, joilla mantelitumake voi myötävaikuttaa kivulle herkistymiseen
hermovauriotilanteissa, ovat vielä huonosti tunnettuja. Tässä työsarjassa tutkittiin
mantelitumakkeesta lähtevän ja selkäytimeen laskevan kivun säätelyn mekanismeja
kokeellisessa hermovauriokivun rottamallissa.
Erityisesti tutkimuksen kohteena oli mantelitumakkeen hapetusstressin merkitys
hermovauriokivun kehittymiselle. Hapetusstressiin tyypillisesti kuuluu
hapetusstressituotteiden ylituotanto sekä vähentynyt hajotus.
Hapetusstressituotteet voivat tunnetusti aktivoida hermosolun kalvon TRP-
ionikanavia, joiden toiminta aikaansaa ja voimistaa kipuviestejä. Tässä työsarjassa
selvitettiin, kuinka mantelitumakkeeseen paikallisesti annostellut TRP-ionikanavien
salpaajat tai hapetusstressituotteiden vastavaikuttajat vaikuttivat hermovamman
aiheuttamaan kivulle herkistymiseen ja kivun affektiivisiin vasteeseen.
Tämän lisäksi työsarjassa selvitettiin voiko aivokuorelle annetulla
sähköstimulaatiolla vaimentaa hermovauriokipua. Erityisesti tutkittiin
sekundaarisen (S2) tuntoaivokuoren stimulaation vaikutusta ja mekanismeja, koska
aiemmissa ihmistöissä on S2-aivokuoren transkraniaalisella magneettistimulatiolla
aikaansaatu tehokas kivun lievitys potilailla, jotka ovat kärsineet
hermovauriokivusta, johon tavanomainen lääkehoito on tehonnut huonosti.
Tämän työsarjan tulokset osoittavat, että mantelitumakkeen N-metyyli-D-
aspartaatti reseptorit sekä TRPA1 ja  TRPC4/5 ionikavat myötävaikuttavat
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hermovammaan liittyvän kivulle herkistymistilan kehittymiseen. Myös
mantelitumakkeen hapetusstressi, jonka synnyttämät tuotteet ovat TRP-ionikanavia
aktivoivia tekijöitä, on tulosten mukaan myötävaikuttamassa kivulle herkistymiseen
hermovaurion jälkeen. S2-aivokuoren sähköstimulaatio vaimensi eläinten
kipuviestejä selkäydintasolla, mutta vain jos eläimellä hermovaurio ja siihen liittyvä
herkistyminen kosketusärsykkeille. S2-aivokuoren sähköstimulaation samoin kuin
mantelitumakkeen TRP-kanavien salpauksen ja hapetusstressin eston
hermovauriokipua lievittävä vaikutus välittyi selkäydintasolle ydinjatkoksesta
selkäytimeen laskevien serotonergisten solujen välityksellä, jotka selkäytimen
takasarveen serotoniinia vapauttaessaan aktivoivat 5-HT1A reseptoreita, jotka
vaimentavat kipuviestejä selkäytimen tasolla.
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Actual or potential tissue injury results from noxious stimulation and leads to
acquisition of an unpleasant sensory experience, namely pain. Pain serves as an
alarm system that leads to development of acute withdrawal and chronic aversive
behavior for minimization of further encounter with noxious stimulation.
Accordingly, pain raises our chances for a longer and healthier life. Individuals with
a rare congenital insensitivity to pain usually die from severe injuries in early
adulthood. This is when parents are likely to stop monitoring these individuals for
tissue damage and compensating for pain malfunction [28]. At the opposite
extreme are patients who experience pain from innocuous stimulation (i.e.,
allodynia), increased pain from noxious stimulation (i.e., hyperalgesia), or both (i.e.,
hypersensitivity). The lives of such patients is full of limitations and, therefore, can
result in development of depression and, eventually, suicidal behavior. Although
pain is subjective, it is always unpleasant. Therefore, experiences (e.g. pricking),
that comprise only the sensorial aspect of pain, but fail to elicit negative emotions,
are not recognized as pain by the International Association for the Study of Pain
[109]. This is consistent with reports of lobotomized patients, in whom destruction
of the cortex responsible for encoding of pain unpleasantness kept pain sensations
from becoming bothersome [130]. At the same time, experiences, that comprise
only the emotional aspect of pain [42], can be regarded as pain. In fact, such
experiences can lead to development of somatic (e.g. headache) [15,53] or visceral
painful sensations (e.g. chest pain) [34,37,76].
Typically, however, pain arises from activation of pain receptors, or nociceptors.
Pain that results from normal somatosensory system functioning is called
nociceptive, whereas pain that results from abnormal somatosensory functioning is
called neuropathic. Peripheral neuropathic pain develops in the setting of
peripheral nerve injury, which triggers pronociceptive changes in primary afferent
fibers. In addition, pronociceptive changes can take place at the spinal and
supraspinal levels and, in fact, outlast changes in the periphery [20]. In the short
term, central pronociceptive changes are only functional. In the long term, these
changes can lead to structural alterations [137,138]. Neuropathic pain represents
the most severe and drug-resistant form of chronic pain. In the clinic, less than a
half of neuropathic patients receive satisfactory pain treatment. These numbers are
even lower outside the clinic. One of the main reasons for this lies in the necessity
for progressive increase in the drug dosage that unavoidably leads to development
of intolerable side effects. Furthermore, neuropathic pain predicts adverse
Literature review
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consequences for the patients’ families and a substantial economic burden on
society in the form of healthcare costs and patients’ inability to work [119,120].
Although the processes leading to chronic pain development remain largely
unknown, some of its steps are noteworthy. Patients with chronic pain display an
increase in neuronal sodium channel expression [36] that likely accounts for
development of hyperexcitability and spontaneous firing in nociceptors. Similarly,
animals with experimental persistent pain display greater expression of cation
channels, hyperexcitability of nociceptors, and activation of previously silent
nociceptors [35,73]. Spinal mechanisms for facilitation of nociceptive transmission
involve long-term potentiation (LTP) of synaptic strength between active
nociceptive afferents and target neurons [84]. Spinal LTP requires proinflammatory
activation of microglia, which may also account for a decrease in the inhibitory
potency of a γ-aminobutyric acid (GABA) [26,27]. Furthermore, in the setting of
nerve injury, non-nociceptive afferents can display a nociceptive phenotype [117]
and, together with nociceptive afferents, sprout new branches in the spinal dorsal
horn (SDH) [182] (however, see [7,63]). Altogether, this amplifies nociceptive input
to the brain that, in the long-term, can lead to maladaptive changes, such as a
decrease in descending inhibition and an increase in descending facilitation of
ascending nociceptive transmission (for a review, see [57]).
1.2 Nociceptive pathways
1.2.1 Primary afferent fibers and their spinal targets
In primary afferent nerve fibers, conduction velocity decreases with the diameter of
the fiber and thickness of myelin sheath in the following order: proprioceptive Aα,
mechanosensitive Aβ, thermosensitive Aδ, thermosensitive C (unmyelinated). In
addition, Aδ- and C-fibers can respond to polymodal noxious stimulation and,
therefore, are responsible for nociception (for a review, see [105]). Nociceptive
information from Aδ-fibers is first to arrive at the spinal cord and thus to the brain
for perception of sharp and well-localized pain. Information from C-fibers arrives 1
to 2 seconds later and results in perception of burning and poorly localized pain,
which increases in intensity with repetition of noxious stimulation. Furthermore,
this second pain can outlast noxious stimulation and activation of C-fibers, and,
therefore, likely, plays a greater role in neuropathic pain than Aδ-fibers [127].
Primary afferents project to the SDH, from where they follow separate pathways.
Aδ- and C-fibers form synapses with interneurons as well as with projection
neurons, axons of which cross the midline and ascend through the anterolateral
column to the brain. In addition, non-nociceptive fibers of primary afferents form
Literature review
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synapses in the SDH, although their major branches ascend to the brain directly
through the ipsilateral dorsal column. In the superficial layers of the SDH, projection
neurons are mostly nociceptive specific, whereas, in deeper layers, they act as
wide-dynamic-range (WDR) neurons, which converge nociceptive and non-
nociceptive inputs [175].
1.2.2 Gate control theory of pain
Although reciprocal principles for encoding of nociceptive and non-nociceptive
information in the spinal cord remain largely unknown, some of them appear to be
consistent  with  the  gate  control  theory  of  pain  [108].  The  theory  rests  on
observations that, although both non-nociceptive and nociceptive afferents excite
projection neurons, they display opposite effects on spontaneous inhibition of
projection neurons by interneurons. In particular, non-nociceptive afferents directly
facilitate inhibitory action of interneurons, whereas nociceptive afferents indirectly
attenuate it (Fig. 1). The theory therefore suggests a circuitry, in which branches of
non-nociceptive afferents can reduce ascending nociceptive transmission by
“closing” the gates to projection neurons.
Interestingly, the gate control theory also indicates that, because non-nociceptive
information is first to arrive at the somatosensory cortex, it likely sets receptivity of
cortical neurons for the following nociceptive input and activates descending
pathways for modulation of the gate control system in the spinal cord. Moreover,
because the somatosensory cortex displays somatotopic arrangement, it likely
triggers descending modulation capable of achieving a high level of spatial
accuracy.
In addition, the gate control theory suggests that, because projection neurons
receive nociceptive information both from visceral and somatic afferents
(viscerosomatic convergence), the former may “open” the gates for the latter and,
thus, refer the sense of pain from the viscera to elsewhere in the body. The theory
therefore explains why myocardial ischemia may lead to pain development, for
instance, in the left shoulder.
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Figure 1. Gate control theory of pain. Projection neurons in the spinal dorsal horn receive main
excitatory input from nociceptive C-fibers and minor excitatory input from non-nociceptive Aβ-
fibers. In addition, C-fibers can excite a chain of two inhibitory interneurons and, thereby,
disinhibit nociceptive transmission through projection neurons. Aβ-fibers, on the other hand, can
impede such disinhibition by exciting the second inhibitory interneuron.
Literature review
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1.2.3 Ascending nociceptive pathways
In the brain (Fig. 2), projection neurons form the most prominent connections with
the thalamus, to which they ascend directly or via the brainstem reticular formation
[181]. The thalamus, in turn, relays nociceptive information to the somatosensory
cortex, which encodes the sensory-discriminative aspect of pain, and to the
anterior-cingulate [174] and insular cortices [21], which, in contrast, encode the
affective-motivational aspect. Additional projection neurons ascend to the superior
colliculus (SC), which promotes visual identification of noxious stimulation [131], to
the periaqueductal gray (PAG), which acts as the opioidergic center for pain
modulation [124], and to the parabrachial nucleus (PbN), which constitutes a part
of the ascending arousal system [150]. Furthermore, the PbN relays nociceptive
information to the hypothalamus [102,104] for regulation of endocrine responses
and to the central nucleus of the amygdala (CeA) for development of avoidance
behavior [12,90].
1.2.4 Descending nociceptive pathways
Medullary neurons descend to the spinal cord (Fig. 2), where they modulate
nociceptive transmission from primary afferent fibers to projection neurons
[56,93,151,158]. In turn, the rostral ventromedial part of the medulla (RVM)
represents a target for direct modulation by higher brain structures, such as the
locus coeruleus, PbN, PAG, SC, and hypothalamus [19,22,139,157,167,176].
Furthermore, indirect sources of RVM modulation can originate from the CeA,
striatum (Str), primary motor cortex and likely from the S2 [4,9,10,49,59,86,87,171-
173]. Such circuitry forms the neural basis for appropriate adjustment of pain
threshold in a constantly changing environment. Chronic nerve injury, however, can
lead to its dysregulation and, thereby, to development of pain hypersensitivity.
Literature review
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Figure 2. Ascending (left) and descending (right) nociceptive pathways.
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The RVM projects  to the spinal  cord with axonal  collaterals  terminating along the
rostrocaudal axis in both the spinal ventral horn and SDH [93]. It thereby acts as a
relay for descending modulation of the vasomotor tone and nociception [33].
Originating from the RVM serotonergic (5-hydroxytryptamine; 5-HT) medullospinal
neurons display partial topographic specificity. In particular, neurons that display
co-localization of 5-HT with peptides terminate in the ventral horn and deep layers
of the SDH [61,75,107]. On the other hand, neurons that display co-localization of
5-HT with GABA terminate exclusively in superficial layers of the SDH [24,107].
GABA acts as an inhibitory neurotransmitter in healthy animals, and, as evident at
the supraspinal level, 5-HT neurons can express GABA receptors [170]. Therefore,
GABA may calibrate the release of 5-HT from medullospinal neurons and its
diffusion to adjacent neurons (i.e., volume transmission [1]) by the means of
autoinhibition in the SDH. At  a  high level  of  volume transmission,  all  neurons can
act as a 5-HT target. Depending on the receptor type they express, however,
activation of a 5-HT receptor can result in either inhibition (e.g. 5-HT1) or facilitation
(e.g. 5-HT2-4) of neuronal activity (for a review, see [41]). Furthermore, whether
such modulation of neuronal activity in the SDH leads to pro- or antinociception
depends on the role 5-HT target neurons play in nociception (transmission,
facilitation, or inhibition).
Activation of GABAA receptors leads to an influx of chloride anions and cell
hyperpolarization. The transmembrane gradient of chloride anions is then restored
by the chloride exporter KCC2. In neuropathic conditions, however, a decrease in
KCC2  expression  leads  to  a  lower  inhibitory  potency  of  GABA.  Such  loss  of  GABA-
mediated inhibition in the SDH contributes to development of chronic pain [27],
whereas in the ventral horn, this loss leads to development of spasticity. In the
latter  case,  however,  a  decrease  in  KCC2  expression  results  from  the  loss  of
descending 5-HT input [18]. It is therefore likely that chronic pain develops (at least
in part) for a similar reason [32,46].
In the RVM, 5-HT neurons display slow and steady discharge that fails to change in
response to noxious stimulation. Such discharge is exclusive to 5-HT neurons and
indicates their role in tonic modulation of pain [106]. For dynamic modulation, on
the other hand, non-5-HT neurons are most likely responsible. Non-5-HT neurons
respond to noxious stimulation with either transient inhibition (OFF cells) or
facilitation (ON cells) of their discharge. In OFF cells, ongoing discharge positively
correlates with antinociception, whereas in ON cells, ongoing discharge positively
correlates with pronociception [56]. The role of non-5-HT neurons that fail to
respond to noxious stimulation, however, remains unclear. Together with 5-HT
Literature review
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neurons, unresponsive to noxious stimulation non-5-HT neurons constitute the
population of NEUTRAL cells [106].
1.4 Amygdala
1.4.1 Role of the amygdala in Pavlovian conditioning
After pairing with an unpleasant stimulus, a neutral cue can become aversive,
whereas, after pairing with a pleasant stimulus, it can become appetitive. Thus,
depending on the conditions, a neutral cue can acquire either a negative or a
positive emotional value. Such conditioning was first demonstrated more than a
century ago by Ivan Pavlov, who could induce salivation in dogs with a sound of a
bell after pairing it with feeding. Furthermore, replacement of an auditory with a
noxious signal produced the same effect without any signs of pain. A reward of
feeding likely compensated for the unpleasantness of noxious stimulation and, in a
sense, led to the dogs’ comprehension of the phrase “no pain, no gain”. However,
noxious stimulation of a body part, which remained intact during pairing, did result
in unbearable pain [108,122]. In Pavlovian conditioning, pain inhibition therefore
requires a circuitry for precise localization of noxious stimulation and previous
experience. Later studies revealed that this circuitry incorporates a limbic brain
area,  the  amygdala,  which  can  indirectly  (via  the  RVM)  regulate  processing  of
nociception throughout the spinal cord and, thereby, modulate pain threshold at
different body sites [58,59,93]. In addition, the amygdala acts as a junction of
pathways for polymodal sensations and emotions. The amygdala predetermines
whether collision of nociceptive and non-nociceptive signals will lead to the ability
of the latter to elicit negative emotions in the future, such as fear [90]. Pain-related
fear  represents  acute  stress  that  can  raise  the  pain  threshold  and  prepare  the
animal for the fight-or-flight response [58,59]. In chronic stress, however, fear
transitions to anxiety and susceptibility to pain increases [91]. Chronic stress and
anxiety represent major complaints among neuropathic patients (e.g. [129,132])
and imply that the amygdala exerts a role in pain chronification [72,74,94,112,147].
1.4.2 Role of the amygdala in nociception
The amygdala (Fig. 3) consists of a group of nuclei, each having distinct connections
with pain-modulating brain structures (for a review, see [115]). The lateral
amygdaloid nucleus (LA) receives polymodal sensory information from the
thalamocortical network and sends it to the basolateral amygdaloid nucleus (BLA),
which, in turn, relays it to the central amygdaloid nucleus (CeA) and to the medial
Literature review
17
prefrontal  cortex  (mPFC).  The  BLA  projects  to  the  CeA  either  directly  or,  as  the
mPFC, via intercalated mass of inhibitory interneurons (ITC cells) in the amygdala
[71,143]. The CeA, in addition, receives nociceptive-specific information from the
spinal cord via the PbN and pairs it with inhibitory inputs from ITC cells or with
direct modulatory inputs from the BLA [12,102]. The outcome of such pairing is
then transmitted through the PAG to the RVM [59], which, as the CeA, also receives
nociceptive-specific information from the PbN [139]. The RVM compares
information from the PAG with information from the PbN for regulation of
nociceptive processing in the SDH [59].
Figure 3. Role of the amygdala in nociception.
BLA basolateral amygdaloid nucleus
CeA central amygdaloid nucleus
ITC intercalated cell mass
LA lateral amygdaloid nucleus
mPFC medial prefrontal cortex
PAG periaqueductal gray
PbN parabrachial nucleus
RVM rostral ventromedial medulla
SDH spinal dorsal horn
ThCN thalamocortical network
- -> amygdaloid nociceptive circuitry
–> ascending nociceptive pathways
=> descending nociceptive pathways
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1.4.3 Chronic pain-induced neuroplastic changes in the amygdala
Projections of the BLA to the mPFC allow pain to affect cognitive functions, whereas
projections of the mPFC to amygdaloid ITC cells permit cognition to modulate pain.
In chronic pain states, however, the BLA displays hyperactivity that leads to
preferential excitation of inhibitory interneurons rather than of pyramidal cells in
the mPFC. A decrease in capability of the mPFC to excite inhibitory ITC cells in the
amygdala results in disinhibition of the CeA. Taken together, this leads to
impairment of cognitive functions and pain persistence [71]. The reason for
hyperactivity of amygdaloid nuclei, however, does not lie in the consistent afferent
input from chronic injury. Rather, the injury leads to pain maintenance by changing
the strength of amygdaloid synapses. In brain slices of animals with chronic pain,
potentiation  of  synaptic  transmission  from  LA  to  BLA  [71],  from  BLA  to  CeA
[44,116],  as  well  as  from  PbN  to  CeA  [65]  has  been  shown.  Brain  imaging  studies
revealed amygdaloid hyperactivity in arthritic patients [85], whereas neuropathic
patients display a decrease in amygdaloid activity as a result of long- but not short-
term pain relief [47]. GABAergic inhibition of the amygdala in neuropathic animals
leads to attenuation of pain hypersensitivity and affect [123], whereas stimulation
with corticosterone in healthy animals leads to development of behavioral and
spinal hypersensitivity [51,128]. Overall, these findings support the hypothesis that
peripheral nerve injury increases amygdaloid activity, which accounts for
supraspinal pain chronification.
1.4.4 Role of the amygdala in stress
1.4.4.1 General adaptation syndrome
In biology, interchange between damage and defense induces stress, which consists
of three stages. The first stage features activation of the sympathetic nervous
system for execution of defense behavior or, in other words, of the fight-or-flight
response. The second stage involves the synthesis and release of glucocorticoids
into the bloodstream to help to cope with stress. However, if stress continues, the
third stage takes place, in which exhaustion, malfunction, and degradation of the
body are evident. The first and second stages imply a normal general adaptation to
stress agents (stressors), whereas the third stage indicates emergence of the
adaptation disorder. Moreover, our susceptibility to stressors as well as their
combination and specificity of action determine what type of a disorder develops
[148]. In this light, neuropathic pain—a disorder in its own right—represents a
result of abnormal adaptation to nerve injury. Therefore, expanding our
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understanding of the mechanisms of stress maladaptations in the setting of nerve
injury can provide new insights into the basis for neuropathic pain.
1.4.4.2 Hypothalamic-pituitary-adrenocortical axis
Acute stress activates sympathetic system, which enhances brain activity through
elevation of sugar and oxygen blood levels. This allows rapid decision-making on
how to minimize external danger. In addition, stress triggers a slower, yet a longer-
lasting response characterized by a release of corticotropin-releasing factor (CRF)
from the paraventricular nucleus (PVN) of the hypothalamus (for reviews, see
[16,60]). CRF stimulates production of adrenocorticotropic hormone (ACTH) and
beta-endorphin from pro-opiomelanocortin in the pituitary gland [103]. ACTH
promotes production of glucocorticoids in the adrenal cortex, whereas beta-
endorphin suppresses pain. The latter, in part, explains the analgesia evident in
acute stress, during which, however, non-opioid mechanisms also take place [145].
Experimental lesions of the BLA and medial amygdaloid nucleus in rats reveal a
decrease in activation of the hypothalamic-pituitary-adrenocortical (HPA) axis
during acute emotional  stress  [13,29],  whereas lesions of  the CeA fail  to have any
effect [29,126]. On the other hand, lesions of the CeA dampen responses of the
HPA axis to acute inflammatory stress [185] and late activation of the
parasympathetic system in acute pain stress. Furthermore, CeA lesions abolish both
early sympathetic and late parasympathetic responses to stimuli paired with acute
pain stress [140]. Taken together, these studies demonstrate that amygdaloid
nuclei play a pivotal role in stress regulation by initiating stress responses of the
HPA  axis  and  recovery  from  stress-induced  sympathetic  activation,  as  well  as  by
forming and replaying stress memory (i.e., conditioning).
1.4.4.3 Corticotropin-releasing factor
Interestingly, the amygdala represents a major site for expression of CRF and its
receptors outside the hypothalamus, suggesting a leading role of CRF circuitry in
orchestrating stress and pain responses. In particular, the lateral hypothalamus (LH,
through a release of CRF) and PbN (through a release of calcitonin gene-related
peptide) innervate CRF-containing neurons in the CeA. In return, CRF-containing
neurons  in  the  CeA  project  back  to  the  LH  and  PbN.  It  is  likely  that  these  CRF
projections from the CeA regulate ascending nociceptive transmission through the
LH and PbN. In addition, the CeA both directly and indirectly (through the bed
nucleus of the stria terminalis) innervates CRF-containing neurons in the PVN of the
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hypothalamus and, thus, likely regulates stress responses of the HPA axis (for a
review, see [50]).
CRF  in  the  amygdala  acts  on  two  G-protein-coupled  receptors:  an  excitatory  CRF1
receptor and inhibitory CRF2 receptor  [69].  Blocking  CRF1 receptors in the CeA
prevents shock-induced freezing [6], whereas its activation leads to synaptic
facilitation between the CeA and parabrachial terminals and to greater neuronal
output of the CeA [67]. In addition, chronic pain leads to synaptic facilitation
between the CeA and the parabrachial  terminals  as  well  as  between the CeA and
BLA. However, blocking CRF1 receptors can inhibit synaptic facilitation, whereas
blocking CRF2 receptors can facilitate it [45]. CRF1 receptors require lower doses of
CRF  for  CeA  stimulation  than  CRF2 receptors do for CeA inhibition [69]. Together,
amygdaloid CRF1 and  CRF2 receptors are likely to be involved in pro- and
antinociceptive actions driven by the amygdala.
Interestingly, although rats with high stress reactivity display pronociception
mediated by CRF1 receptors [66], activation of CRF1 receptors in normal rats results
in pronociception, independent of the HPA axis [67]. The amygdala therefore likely
regulates pain through CRF circuitry distinct from the HPA axis. Repetitive activation
of the HPA axis, however, can initiate pronociceptive changes in amygdaloid
expression of CRF and its receptors. This is consistent with findings showing that
prolonged exposure of the CeA to glucocorticoids raises CRF expression levels in the
CeA of healthy rats that leads to pain facilitation and, likely through sensitization of
the HPA axis, to development of anxiety [51,149,162]. Neuropathic animals also fail
to display any functional deficiencies in the HPA axis and have higher CRF
expression levels in the CeA [141,166].
1.4.4.4 Reactive oxygen species
Glucocorticoids help maintain high brain activity levels by facilitating glucose
availability through glycogenolysis, gluconeogenesis, and lipolysis. Moreover,
glucocorticoids suppress the immune system that results in even greater availability
of glucose for brain consumption (for reviews, see [125,154,155]). In chronic stress,
however, suppression of immune responses and an increase in brain metabolism
raise the risk of cell damage from uncontrolled ROS production (for a review, see
[152]). Animal models of stress, among which are those driven by noxious
stimulation, reveal a dynamic correlation between brain antioxidative activity and
behavior. Initiation of antioxidative activity in the first week of stress corresponds
to a decrease in exploratory behavior, which most likely indicates development of
fear.  In  the  second  week  of  stress,  antioxidative  activity  reaches  its  peak  and
behavior returns to normal. Beyond this period, however, antioxidative activity fails
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and animals display abnormally high exploratory behavior [52], which may mask
development of anxiety [156]. The amygdala therefore, as an essential brain area
for development of fear and anxiety, is likely to be susceptible to oxidative changes
in long-term stress. Moreover, since nerve injury can represent a form of long-term
stress, similar changes in the amygdala likely take place during transition of pain
from an acute to a chronic state.
Induction of hyperalgesia and comorbid anxiety with peripheral administration of
pain-inducing agents is associated with an increase in amygdaloid levels of ROS,
which not only promotes excitatory transmission from the PbN to the CeA but also
elevates excitability and activity of the CeA [68,101]. Similarly, activation of a
metabotropic glutamate receptor type 5 (mGLUR5) in the amygdala induces
hyperalgesia in healthy rats by promoting ROS production and, thereby, elevating
CeA  activity  [97].  The  table  below  demonstrates  that  mGLUR5  is  likely  the  only
metabotropic glutamate receptor, which CeA neurons express on their cell bodies
(Table 1). In light of this notion and the fact that the CeA acts as a sole nucleus of
the amygdala that projects directly to regions, which either transmit ascending
nociception  or  modulate  it,  mGLUR5  emerges  as  the  main  culprit  for  amygdala-
driven pronociception [3,14,54,95,96,133,134].
Table 1. Glutamate receptors in the amygdala and effect of their activation.




mGLUR1 ITC*→CeA presynaptic ↑
mGLUR5 BLA→CeA postsynaptic ↑
II mGLUR2,3 ITC*→CeA presynaptic ↓
III
mGLUR4,7,8 PbN→CeA presynaptic ↓
mGLUR7 ITC*→CeA presynaptic ↑
mGLUR8 BLA→CeA presynaptic ↓
Ionotropic NMDA PbN→CeA postsynaptic ↑
BLA basolateral amygdaloid nucleus
CeA central amygdaloid nucleus





1.4.4.5 Transient receptor potential channels
Transient receptor potential (TRP) channels are non-selective cation channels that
are highly sensitive to cellular redox status. Increase in ROS production leads to
TRP-mediated influx of cations, which can depolarize the cell membrane and act as
second messengers (for a review, see [121]).
From the ankyrin subfamily of TRP channels, mammalian cells express only type 1
(TRPA1), which acts as a sensor for irritant chemicals at C-fibers in the skin [77] and
lungs [114]. There, activation of TRPA1 channels by ROS can lead to sensitization of
C-fibers [2,144] and, thus, to development of pain hypersensitivity [31].
Furthermore, in the SDH of the spinal cord, presynaptic TRPA1 channels facilitate
glutamatergic transmission from primary afferents [80] that likely accounts for
development of secondary hypersensitivity, as evident both in patients [83] and
experimental animals [177]. Similarly, presynaptic TRPA1 channels facilitate
glycinergic transmission onto medullary dorsal horn neurons [25]. Considering that
glutamate and glycine act as co-agonists of N-methyl-D-aspartate (NMDA) channels,
this suggests that activation of TRPA1 channels can lead to activation of NMDA
channels. Although NMDA channels in the CeA account for maintenance of
neuropathic pain [3], the contribution of TRPA1 channels to pronociceptive changes
in the CeA remains unknown.
From the canonical subfamily of TRP channels (TRPC), the amygdala expresses type
1,  4,  and  5,  which  unite  to  form  two  heteromeric  complexes:  TRPC1/TRPC4 and
TRPC1/TRPC5.  In  the dorsal  root ganglion of  the sciatic  nerve,  expression of  TRPC4
channels changes bidirectionally, depending on the site of injury and the outcome
(pain  or  regeneration)  [153,183].  In  the  LA,  activation  of  mGLUR1  or  mGLUR5
triggers an intracellular signaling cascade that leads to activation of TRPC4 and
TRPC5 channels responsible for mediating innate but not learned (i.e., pain-related)
fear [38,135,136]. In the CeA of neuropathic animals, however, it remains unknown
whether TRPC4 and  TRPC5 channels are responsible for mediating pain
hypersensitivity and pain affect.
1.5 Somatosensory cortex
As the outer layer of the brain, the cortex provides an opportunity for external
modulation of brain activity with minimum invasion. Since 1991, electrical
stimulation of the primary motor cortex (M1) serves as a safer and more efficacious
method for attenuation of chronic pain in patients than stimulation of the thalamus
[163,164].  Nowadays,  TMS  of  the  M1  provides  a  minimally  invasive  alternative  to
direct electrical stimulation and serves as a method for treatment of two comorbid
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deceases, chronic pain [92,110] and paresis [11,163]. However, TMS of the S2 can
serve as an alternative and efficient method for attenuation of neuropathic pain,
when TMS of the M1 remains inefficacious [99,100,168].
The human primary (S1) and secondary (S2) somatosensory cortices receive
nociceptive and non-nociceptive somatosensory information directly from the
thalamus and process it in parallel [98]. The S2 displays functional topography for
noxious and innocuous stimuli [39]. Furthermore, innocuous stimulation of the
nearby skin can inhibit (i.e., gate) nociceptive activation of the S2, whereas noxious
stimulation cannot [161]. This is consistent with the proposal by Melzack and Wall
[108] that innocuous stimulation may predetermine responses of the S1/S2 to
noxious stimulation and trigger S1/S2-driven modulation of the gate control system
in the spinal cord (see chapter 1.2.2).
In comparison with healthy controls, patients with trigeminal neuralgia [118] or
central post-stroke pain [81] display a smaller volume of the gray matter in the S2,
whereas patients with chronic musculoskeletal pain show greater neural activity in
the S2 during presentation of pain-related words [159]. TMS of the S2 attenuates
acute pain in healthy subjects [100,168] and drug-resistant neuropathic pain in
patients [99]. Importantly, in both cases, the TMS of the S2 produces greater pain
attenuation than TMS of the S1 or M1. In addition, TMS of the S2 attenuates
visceral pain clinically [43], but does not, however, attenuate experimental pain in
interictal migraineurs [165].
In healthy rats, electrical stimulation of the S2 fails to attenuate pain during acute
noxious stimulation, whereas in rats with formalin-induced pain, electrical
stimulation of the S2 produces weak antinociception by itself and strong
antinociception in combination with a neural NO synthase inhibitor at a
subtherapeutic dose [86]. The synergism of the two treatments correlates with c-
Fos expression in the spinal cord and, in part, requires activation of spinal 5-HT
receptors (but not activation of opioid and noradrenergic systems) [87]. Moreover,
following formalin lip injections, S2 stimulation alone can reduce c-Fos expression
in dorsal-horn neurons at the medullary level, suggesting its efficacy against
orofacial pain [49]. Taken together, these findings indicate that S2 stimulation is
capable of attenuating pain through medullospinal 5-HT mechanisms, but only in




The aim of the current work was to test following hypotheses:
 Neuropathic pain results in part from pronociceptive hyperactivity of the
CeA. Therefore, inhibition of the CeA with intraamygdaloid injections of
lidocaine should attenuate neuropathic pain in rats with peripheral nerve
injury but not nociceptive pain in sham-operated rats (IV). Furthermore,
stimulation of the CeA with intraamygdaloid injections of glutamate should
exacerbate neuropathic pain (I).
 Oxidative changes in the CeA contribute to development of pronociceptive
hyperactivity of the CeA. Therefore, intraamygdaloid injections of
antioxidants should attenuate neuropathic pain in rats with peripheral nerve
injury, but not nociceptive pain in sham-operated rats (IV). Furthermore,
intraamygdaloid injections of a ROS donor should recapitulate neuropathic
pain characteristics (e.g. hypersensitivity) in sham-operated rats (IV).
 TRPC4/5 and TRPA1 channels  in  the  CeA  act  as  receptors  for  ROS  (for  a
review, see [121]). Therefore, intraamygdaloid injections of either a TRPC4/5
antagonist (II) or a TRPA1 antagonist (IV) should attenuate neuropathic pain
in rats with peripheral nerve injury, but not nociceptive pain in sham-
operated rats.
In addition, we set to identify medullospinal mechanisms for hypothesized changes
in spinal nociception induced by intraamygdaloid injections (I, IV). Particularly, we
attempted to prevent hypothesized changes either by inhibiting cell bodies of 5-HT
neurons in the RVM (I) or by blocking 5-HT receptors in the spinal cord (I, IV).
We next investigated whether S2 stimulation (III) attenuates neuropathic pain by
reversing medullospinal mechanisms that the CeA engages for descending
facilitation of spinal nociception (I, IV). We assessed the effect of S2 stimulation on
neuropathic and nociceptive pain and recorded the discharge rate of medullary and
spinal neurons in lightly anesthetized rats. Thereafter, we assessed whether the
same dugs that prevented pain attenuation induced by intraamygdaloid injections





All experiments (Table 2) were performed according to the guidelines of European
Communities Council Directive of 22 September 2010 (2010/63/EU). The national
Animal Experiment Board in Finland (ELLA) approved the methods. All efforts were
made  to  limit  distress  and  to  use  only  the  number  of  rats  (RccHan:WIST,  Harlan
Laboratories, Netherlands) necessary to produce reliable scientific data. We
followed the principles of the 3Rs (replacement, reduction, and refinement) in the
design of our experiments [146].
Table 2. Allocation of methods to their corresponding studies.
Study
Surgeries
SNI model I, II, IV
SNL model III
Intracranial cannula implantation I, II, III, IV
Intrathecal catheterization I, IV
Behavioral tests




SNI spared nerve injury




Glutamate (l-glutamic acid monosodium salt), 8-OH-DPAT (8-hydroxy-2-
(dipropylamino)tetralin, 5-HT1A receptor agonist), MK-801 (NMDA receptor
antagonist), ML-204 (TRPC4/5 channel antagonist), naloxone (opioid receptor
antagonist), ondansetron (5-HT3 receptor antagonist), PBN (phenyl-N-tert-
butylnitrone, antioxidant), raclopride (dopamine D2 receptor antagonist), t-BOOH
(tert-butyl-hydroperoxide, ROS donor), TEMPOL (4-hydroxy-2,2,6,6-
tetramethylpiperidine-1-oxyl, antioxidant), WAY-100635 (5-HT1A receptor
antagonist), and A-967079 (TRPA1 channel antagonist) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Atipamezole (α2-adrenoceptor antagonist), lidocaine
(sodium channel blocker), and pentobarbital (GABAA receptor positive allosteric
modulator) were purchased from OrionPharma (Espoo, Finland). CHEMBRIDGE-
5861528 (TRPA1 channel antagonist) was purchased from ChemBridge (San Diego,
CA, USA). Buprenorphine (μ-receptor partial agonist, κ-receptor antagonist) was
purchased from RB Pharmaceuticals Limited (Slough, UK).
3.3 Surgeries
3.3.1 Anesthesia
All surgeries were performed in rats anesthetized with intraperitoneal injections of
pentobarbital at the dose of 60 mg per kg. Additional injections of pentobarbital
were  given  at  the  dose  of  15-20  mg  per  kg  as  needed  to  maintain  deep  level  of
anesthesia. Following surgery, rats received subcutaneous injections of
buprenorphine at the dose of 0.01-0.03 mg per kg for three consecutive days every
twelve  hours.  Rats  were  allowed  to  recover  for  at  least  one  week  before  the
experiments (Fig. 4).
Figure 4. Time course of studies I-IV.
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3.3.2 Spared nerve injury model
The spared nerve injury (SNI; Fig. 5) model of neuropathic pain derives its name
from sparing the sural nerve while cutting the other two branches of the sciatic
nerve (tibial and common peroneal nerves) [30]. Such partial denervation induces
pain hypersensitivity in the lateral plantar surface of the injured paw for six or more
months.
Figure 5. Spared nerve injury model.
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3.3.3 Spinal nerve ligation model
Unilateral  ligation  of  spinal  nerves  L5  and  L6  served  as  a  second  model  of
neuropathic pain [78]. In contrast to SNI, rats with spinal nerve ligation (SNL; Fig. 6)
develop pain hypersensitivity in the entire plantar surface of the injured paw.
Hypersensitivity in the SNL model, however, lasts for a much shorter duration (up
to two months).
Figure 6. Spinal nerve ligation model.
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3.3.4 Intracranial cannula implantation
Anesthetized rats were secured to a stereotaxic frame and a hole was made in the
skull for the implantation of a chronic guide cannula 2 mm above the desired
injection site. The guide cannula was cemented to screws, which, in turn, were
anchored to the skull. During experiments, injections were made with the use of an
internal cannula protruding 2 mm from the tip of the guide cannula. At the
completion of experimental procedures, the rats were euthanized, and injection
sites were identified in the coronally sectioned brain after fixation in formalin.
3.3.5 Intrathecal catheterization
Anesthetized rats were implanted with an intrathecal catheter for lumbar drug
injections. The implantation was considered successful if a lidocaine injection
through the catheter produced temporal paralysis of hind limbs.
3.4 Behavioral tests
3.4.1 Mechanical pain
Rate of paw withdrawal during mechanical stimulation with ascending series of
calibrated von Frey filaments indicated the level of mechanical pain sensitivity.
3.4.2 Heat pain
Latency of paw withdrawal during heat stimulation with a Peltier thermode
indicated the level of heat pain sensitivity.
3.4.3 Emotional pain
To evaluate the aversive component of pain, an aversive place-conditioning
paradigm was used [89], in which a neuropathic rat resided in a chamber divided
into two halves, one dark and the other illuminated. In the dark half, the injured
paw was stimulated, whereas, in the illuminated half, the healthy paw was
stimulated. As a result, the rat chose the illuminated half over the more naturally
preferable dark half. A drug-induced increase in time the rat spent in the dark half




The discharge rate of neurons was recorded with an extracellular electrode in
lightly anesthetized rats secured to a stereotaxic frame. In the RVM, neurons giving
excitatory responses to noxious stimulation were considered as pronociceptive ON
cells, whereas those giving inhibitory responses were considered as antinociceptive
OFF cells [56]. In the SDH, neurons giving excitatory responses to both noxious and
innocuous stimulation were considered as pain-relaying WDR cells.
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4 RESULTS AND DISCUSSION
4.1 Medullospinal 5-HT neurons as a relay for bidirectional
modulation of pain hypersensitivity by the amygdala (I, IV)
As a first step in investigating the role of the amygdala in neuropathic pain, we
studied how inhibition of the right CeA with lidocaine influences pain in
neuropathic and non-neuropathic conditions. We chose the right CeA as it plays a
greater role in the development of inflammatory pain than the left CeA,
independent of the location of inflammation [23,70]. Furthermore, the right CeA
was contralateral to the nerve injury. A previous study in similar settings
demonstrates greater pronociceptive changes in the right CeA than in the left one
[65].  In  our  experiments,  lidocaine  injection  (4  %,  0.5  μl)  into  the  CeA  attenuated
pain hypersensitivity in neuropathic rats (SNI model) but not nociceptive pain in
sham-operated rats (Table 3). This indicates that pain hypersensitivity in peripheral
neuropathy develops, at least in part, due to pronociceptive hyperactivity of the
CeA. This is consistent with other studies, which demonstrate positive correlation
of amygdaloid activity with the level of chronic pain [44,47,65,71,85,116].
However, because lidocaine inhibits both neurons that originate from the CeA and
neurons that pass through the CeA, our second step was to investigate how pain
hypersensitivity changes during modulation of synaptic activity in the CeA with
various  doses  of  glutamate.  A  high  dose  of  glutamate  (100  μg)  in  the  CeA
attenuated hypersensitivity, whereas a low dose of glutamate (9 μg) facilitated it.
Furthermore, blocking NMDA receptors in the CeA with MK-801 prevented
facilitation of hypersensitivity induced by a low dose of glutamate but not
attenuation of hypersensitivity induced by a high dose of glutamate. In these
experiments, we pretreated the CeA with MK-801 at a dose that was too low to
influence pain hypersensitivity by itself. However, in another set of experiments,
attenuation of pain hypersensitivity was evident after the dose of MK-801 was
elevated. Taken together, this suggests that, in the CeA of neuropathic animals,
endogenous release of glutamate causes activation of NMDA receptors that
dominates over activation of non-NMDA glutamate receptors. As a result, the CeA
displays pronociceptive hyperactivity in neuropathy. This is consistent with a
previous study that demonstrates contribution of NMDA receptors in the CeA to
development of pain hypersensitivity [3]. On the other hand, there is also evidence
that non-NMDA glutamate receptors in the CeA modulate pain hypersensitivity
bidirectionally, depending on their type and site of expression [54,96,116,134].
However, it was outside the scope of this thesis to identify which non-NMDA
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glutamate receptors in the CeA mediated attenuation of hypersensitivity induced
by a high dose of glutamate.
To determine if CeA treatment with a high dose of glutamate attenuates
hypersensitivity by exerting its action at the spinal cord level, we attempted to
prevent antinociceptive action of glutamate by blocking spinal receptors, which are
normally associated with antinociception (for a review, see [111]). Blocking 5-HT1A
receptors with WAY-100635 prevented attenuation of hypersensitivity induced by a
high dose of glutamate in the CeA, whereas blocking α2-adrenoceptors (with
atipamezole), or dopamine D2 receptors (with raclopride), or opioid receptors (with
naloxone) failed to do the same. Furthermore, spinal injections by themselves had
no effect on hypersensitivity at the currently used doses. Considering that 5-HT in
the spinal cord originates entirely from supraspinal regions [88], this indicates that
the antihypersensitivity effect induced by a high dose of glutamate in the CeA is
mediated primarily by spinally projecting 5-HT neurons. This is consistent with
other studies, which demonstrate the importance of spinal 5-HT1A receptors in
mediating attenuation of hypersensitivity in neuropathic [179] and other
pathological pain states [48,186].
To determine if spinally projecting 5-HT neurons also mediate facilitation of
hypersensitivity induced by a low dose of glutamate in the CeA, we attempted to
prevent the pronociceptive action of glutamate by blocking the spinal 5-HT3
receptor, which is normally associated with pronociception (for a review, see
[111]). Blocking 5-HT3 receptors with ondansetron, which alone had no effect on
hypersensitivity (i.e., at the currently used dose), prevented facilitation. This
indicates that spinally projecting 5-HT neurons in the medulla can relay both
facilitation and attenuation of hypersensitivity from the CeA. Although this is
consistent with other studies, which demonstrate contribution of spinal 5-HT3
receptors to the development of hypersensitivity, there is also evidence of their
role in mediating antihypersensitivity. Such controversy may result from the fact
that activation of spinal 5-HT3 receptors can lead to the release of spinal GABA [55],
the inhibitory potency of which can disappear at certain stages of chronic pain
development [26,27].
We next investigated whether medullospinal neurons act as sources of 5-HT in the
spinal cord for bidirectional modulation of hypersensitivity by the CeA. We were
particularly interested in the role of the RVM, which accounts for antinociception in
pain-related fear mediated by the amygdala [58,59]. We therefore pretreated the
RVM  with  a  5-HT1A autoreceptor agonist (8-OH-DPAT) in an attempt to
hyperpolarize cell bodies of 5-HT neurons [142]. Although RVM pretreatment with
8-OH-DPAT by itself failed to influence hypersensitivity, 8-OH-DPAT in the RVM
prevented both facilitation of hypersensitivity induced by a low dose of glutamate
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and attenuation of hypersensitivity induced by a high dose of glutamate in the CeA.
This indicates that the CeA regulates activation of spinal 5-HT receptors through a
release of 5-HT from neurons, which descend to the spinal cord from the RVM.
However,  it  remains  unknown  how  the  CeA  exerts  its  bidirectional  action  on
hypersensitivity by activating the same medullospinal 5-HT neurons. It is possible
that the CeA selectively activates either pronociceptive 5-HT3 receptors or
antinociceptive 5-HT1A receptors by activating different subtypes of medullospinal
5-HT neurons. Alternatively, the CeA may regulate the level of net activity of
medullospinal 5-HT neurons and, thereby, titrate the release of 5-HT in the spinal
cord. This notion is supported by the findings that treatment of the RVM with a low
dose of glutamate leads to facilitation of nociceptive pain, whereas treatment with
a  high  dose  results  in  attenuation  [187].  Moreover,  5-HT  neurons  in  the  RVM
account for both weak and strong attenuations of nociceptive pain induced by
treatment of the PAG with low and high doses of morphine, respectively [17].
In conclusion, endogenous release of glutamate predominately leads to activation
of NMDA receptors, which maintain pronociceptive hyperactivity of the CeA. The
CeA, in turn, exerts its pronociceptive hyperactivity by preventing antinociceptive
activation of medullospinal 5-HT neurons.
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Table 3. Medullospinal 5-HT neurons as a relay for bidirectional modulation of pain
hypersensitivity by the amygdala.
CeA injections


































CeA central amygdaloid nucleus
GLU100 100 μg of glutamate
GLU9 9 μg of glutamate
LIDO lidocaine
RVM rostral ventromedial medulla
SDH spinal dorsal horn







4.2 Reactive oxygen species as a culprit for pronociceptive
hyperactivity of the amygdala (II, IV)
In light of recent findings [97] that glutamate in the CeA can exacerbate nociceptive
pain by promoting production of ROS, we addressed the role of ROS in the
development of neuropathic pain. To test this, we first assessed how treatment of
the CeA with antioxidants (TEMPOL and PBN) influences pain in neuropathic and
non-neuropathic conditions. Treatment of the CeA with either of the two
antioxidants attenuated pain hypersensitivity in neuropathic rats (SNI model). In
sham-operated rats, however, neither TEMPOL nor PBN influenced nociceptive pain
(Table 4). Thereafter, we addressed whether attenuation of pain affect
accompanies attenuation of hypersensitivity in neuropathic rats after treatment of
the CeA with antioxidants. We chose TEMPOL from the two antioxidants and
observed that it attenuates pain affect. This suggests that neuropathy induces
oxidative changes in the CeA that may account for its pronociceptive and pain-
affect-inducing hyperactivity. This is consistent with other studies demonstrating
contribution of ROS in the CeA to the development of visceral pain and bee venom-
induced pain [68,101].
Because ROS act as endogenous agonists of TRP channels (for a review, see [121]),
we  next  investigated  if  TRPC4/5 and  TRPA1 channels in the CeA mediate observed
oxidative changes. We therefore assessed how treatment of the CeA with
antagonists of a TRPC4/5 channel  (ML-204)  and of  a  TRPA1 channel (CHEMBRIDGE-
5861528) influences neuropathic pain. Similar to antioxidants, ML-204 and
CHEMBRIDGE-5861528 in the CeA separately attenuated both pain hypersensitivity
and pain affect in neuropathic rats but not nociceptive pain in sham-operated rats.
In addition, attenuation of hypersensitivity was evident after blocking TRPA1
channels with an antagonist structurally different from CHEMBRIDGE-5861528, A-
967079. Taken together, this indicates that, in neuropathy, ROS account for
pronociceptive and pain affect-inducing hyperactivity of the CeA by acting on
TRPC4/5 and TRPA1 channels. This is somewhat contrary to other studies, in which
TRPC4/5 channels in the amygdala failed to play a role in pain-related fear [135,136].
However, this controversy can be explained by the fact that these studies
investigated  the  role  of  TRPC4/5 channels in the LA, whereas we focused on their
role in the CeA. Additionally, these studies [135,136] demonstrate inability of
TRPC4/5 channels to influence pain-related fear in healthy (knockout) animals,
whereas we examined the ability of TRPC4/5 channels to influence pain affect only in
neuropathic animals. Considering, however, that, in our experiments, blocking
TRPC4/5 channels failed to attenuate nociceptive pain in non-neuropathic (sham-
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operated) animals, it is likely that TRPC4/5 channels account for pain affect and pain-
related fear only in the setting of nerve injury.
Since activation of 5-HT1A receptors in the spinal cord accounted for attenuation of
hypersensitivity induced by a high dose of glutamate in the CeA, we next
investigated whether they also account for attenuation of hypersensitivity seen
after blocking TRPA1 channels in the CeA with CHEMBRIDGE-5861528. As expected,
blocking spinal 5-HT1A receptors  with  WAY-100635  at  a  dose  that  alone  failed  to
influence hypersensitivity prevented the antihypersensitivity effect of
CHEMBRIDGE-5861528. Considering that a high dose of glutamate in the CeA
attenuates hypersensitivity by activating medullospinal 5-HT neurons, this suggests
that blocking TRPA1 channels in the CeA leads to a similar activation of
medullospinal 5-HT neurons.
Encouraged by above findings, we attempted to recapitulate hypersensitivity in
sham-operated  rats  by  treating  the  CeA  with  a  ROS  donor,  t-BOOH.  Although,  t-
BOOH in a previous study exacerbated nociceptive pain after administration into
the spinal cord [180], it failed to do so in the current study after administration at
the same dose into the CeA. This indicates that acute administration of ROS alone is
insufficient to induce pronociceptive changes in the CeA and thus suggests that its
chronic administration or presence of comorbid factors (or both) is necessary.
In conclusion, ROS prevent antinociceptive activation of medullospinal 5-HT
neurons by promoting pronociceptive hyperactivity of the CeA.
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4.3 Medullospinal 5-HT neurons as a relay for attenuation of
neuropathic pain by cortical stimulation (III)
TMS of the S2 has proven to be an efficacious method for attenuation of drug-
resistant pain in neuropathic patients [99]. However, because the mechanism of
pain attenuation remains largely unknown, we examined whether descending
pathways, which are activated by S2 stimulation, overlap with those pathways that
are  activated  by  a  high  dose  of  glutamate  in  the  CeA.  We  therefore  investigated
whether medullary 5-HT or non-5-HT neurons contribute to S2 stimulation-induced
pain attenuation in neuropathic rats. To test this, we recorded neurons in the RVM
in parallel with behavioral assessment of pain. In addition, we separately recorded
pain-relay neurons in the SDH. However, because SDH recordings required
irrecoverable surgical preparations (laminectomy), we performed them in lightly
anesthetized rats. Furthermore, to obtain comparable data, assessment of pain
behavior and simultaneous recordings of medullospinal neurons were also
performed in lightly anesthetized rats. However, because light anesthesia
diminishes the withdrawal reflex, we used a piezoelectric movement detector over
the gastrocnemius muscle to assess the reflex mechanomyographically.
Furthermore, we replaced noxious mechanical stimulation with noxious heat
stimulation to eliminate artifacts in the mechanomyogram. This, in turn, required
implementation of the SNL model of neuropathic pain instead of the SNI model to
enlarge the hypersensitive surface of the paw at the expense of the duration of
hypersensitivity: two months in SNL rats versus six (or more) months in SNI rats
[30,78].
Stimulation of the S2, independent of the hemisphere, attenuated heat pain in
nerve-injured rats with mechanical hypersensitivity. Attenuation of heat pain was
evident at the lowest cortical stimulus intensity of 30 μA (0.1-ms pulses at 300 Hz).
The antinociceptive effect failed to increase at higher intensities of 50 and 70 μA.
This suggests that pain attenuation was induced by stimulation of the S2 and not by
a possible spread of electrical current to adjacent regions. Stimulation of the right
S2 (contralateral to the injury), however, failed to attenuate heat pain in sham-
operated rats and in rats that failed to develop mechanical hypersensitivity after
SNL (Table 5). Although it remains unknown whether S2 stimulation in the left
hemisphere attenuates pain in sham-operated and non-hypersensitive neuropathic
rats, this suggests that S2 stimulation, at least in the right hemisphere, is efficacious
only in animals with pathological pain hypersensitivity. This is consistent with




Thereafter, we performed recordings in the SDH during stimulation of the right S2
to investigate spinal mechanisms for behavioral attenuation of heat pain in
hypersensitive neuropathic rats. In particular, we recorded wide-dynamic range
(WDR) cells, which accelerated their discharge rate in response to both noxious
heat stimulation and innocuous mechanical stimulation of the injured paw. We
observed  that  S2  stimulation  attenuates  heat  responses  of  WDR  cells  (Fig.  7).  We
observed also that this attenuation can be prevented by blocking spinal 5-HT1A
receptors with WAY-100635 at a dose that alone failed to reduce heat-response
discharge. Considering that, at the current dose, WAY-100635 also failed to reduce
the ongoing discharge rate of WDR cells, this suggests that S2 stimulation
attenuated pain by activating 5-HT1A receptors, which are presynaptic to WDR cells.
However, one must be cautious with this interpretation, since failure of WAY-
100635 to reduce the ongoing discharge rate of WDR cells may have resulted from
the fact that the ongoing discharge rate of WDR cells was originally very low. On the
other hand, a recent whole-cell patch clamp study in spinal cord slices supports our
interpretation of presynaptic localization of 5-HT1A receptors, by demonstrating
that  5-HT  in  the  SDH  inhibits  nociceptive  transmission  via   activation  of  5-HT1A
receptors, which are localized on spinal terminals of primary afferents [160].
Figure 7. Example of recordings in the spinal dorsal horn.
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Because both electrical stimulation of the S2 and glutamatergic stimulation of the
CeA attenuate pain in hypersensitive neuropathic rats by activating spinal 5-HT1A
receptors,  it  is  likely  that  they  do  so  through  the  same  mechanism.  To  test  this
hypothesis, we attempted to prevent S2 stimulation-induced pain attenuation by
pretreating  the  RVM  with  an  agonist  of  5-HT1A autoreceptors (8-OH-DPAT), which
prevented pain attenuation induced by a high dose of glutamate in the CeA. In the
S2 experiments,  as  in  the CeA experiments,  we used 8-OH-DPAT at  a  dose,  which
failed to influence pain by itself. In support of our hypothesis, 8-OH-DPAT
prevented S2 stimulation-induced pain attenuation. As in the CeA experiments, we
presume that 8-OH-DPAT acted by inhibiting cell bodies of spinally projecting 5-HT
neurons. This indicates that activation of medullospinal 5-HT neurons is a necessary
step for the S2 stimulation-induced pain attenuation, as it is for pain attenuation
induced by a high dose of glutamate in the CeA. However, it remains unknown
whether S2 stimulation and a high dose of glutamate in the CeA attenuate pain by
recruiting the same subtypes of medullospinal 5-HT neurons or by regulating their
net activity in a similar fashion.




In addition, we recorded heat responses of pain-regulating ON and OFF cells in the
RVM, which are shown to be non-5-HT [106].  Unlike WDR cells  in  the SDH, which
respond to both noxious and innocuous stimulations, ON and OFF cells in the RVM
respond only to noxious stimulation. Furthermore, ON cells respond by accelerating
their discharge rate before withdrawal of the paw, whereas OFF cells respond by
decelerating it. A fast discharge rate of ON cells and a slow discharge rate of OFF
cells predict facilitation of nociception, whereas a slow discharge rate of ON cells
and a fast discharge rate of OFF cells predict inhibition of nociception [56].
However,  in  our  experimental  setup,  we  were  unable  to  record  ON  and  OFF  cells
during S2 stimulation, because the cortical stimulation electrode induced stimulus
artifacts, which masked all neural spikes during stimulation. Therefore, we were
able  to  record  ON  and  OFF  cells  only  after  cessation  of  S2  stimulation  when
attenuation of pain behavior was marginal. Nonetheless, we observed that S2
stimulation shortens duration of heat responses in ON cells and prolongs the
latency of heat responses in OFF cells (Fig. 8). Considering that at least some of the
ON  and  OFF  cells  project  to  the  SDH  [40,169],  this  suggests  that  S2  stimulation
promotes antinociceptive activity of both non-5-HT (i.e., ON and OFF cells) and 5-HT
medullospinal neurons. Therefore, our findings are consistent with a previous study
[87], where unselective inhibition of spinal 5-HT receptors prevented pain
attenuation induced by S2 stimulation. Interestingly, the same study [87]
demonstrates also the insignificance of the opioid and noradrenergic systems in S2
stimulation-induced pain attenuation, which narrows the list of candidates for the
role of (presumably medullospinal) non-5-HT neurons engaged by S2 stimulation in
our study.
In conclusion, S2 stimulation represents a clinically relevant method that has the
potential to recover antinociceptive activity of medullospinal 5-HT neurons, which
is suppressed in neuropathy due to pronociceptive hyperactivity of the CeA.
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The present studies suggest that, in neuropathic conditions, endogenous release of
glutamate in the CeA predominantly activates NMDA (rather than non-NMDA)
receptors, which maintain pronociceptive hyperactivity of the CeA (I). However,
activation of non-NMDA glutamate receptors in the CeA can lead to attenuation of
pain hypersensitivity, which is likely due to suppression of pronociceptive
hyperactivity of the CeA. CeA-induced pronociception results from activation of
spinal 5-HT3 receptors, whereas CeA-induced antinociception results from
activation of spinal 5-HT1A receptors. Interestingly, activation of both spinal 5-HT3
and 5-HT1A receptors requires activation of medullospinal 5-HT neurons. This
indicates that the CeA normally promotes antinociceptive activity of medullospinal
5-HT neurons, whereas, in neuropathy, the CeA starts to promote their
pronociceptive activity. It is likely that medullospinal 5-HT neurons have two
distinct subtypes, one of which relays antinociception, whereas the other accounts
for pronociception, similar to medullospinal non-5-HT neurons (antinociceptive OFF
cells and pronociceptive ON cells) [40,56,106,169]. Alternatively or additionally, the
level of net activity of medullospinal 5-HT neurons may determine the final effect
on nociception.
We also provide evidence that ROS in the CeA can promote pronociceptive
hyperactivity of the CeA through activation of TRPA1 and TRPC4/5 channels (II, IV). In
light of these observations, an increase in ROS production and a decrease in ROS
detoxification in the CeA emerge as possible maladaptive changes that account for
the development of neuropathic pain. Furthermore, considering that ROS represent
a product of mitochondrial activity (for a review, see [113]), neuropathic pain can in
part represent a mitochondrial disorder. This is consistent with previous findings
that chemotherapy induces neuropathic pain by promoting accumulation of
atypical mitochondria in peripheral nerves, which is associated with ROS
overproduction and poor ROS detoxification [8,184].
In addition, we established that S2 stimulation attenuates neuropathic pain by
inhibiting spinal transmission of nociceptive information through WDR cells ( III). To
accomplish this, S2 stimulation employs medullospinal 5-HT neurons to activate
spinal 5-HT1A receptors, which are likely presynaptic to WDR cells. Interestingly,
such mechanism for pain attenuation in SNL rats is similar to the one that the CeA
engages in SNI rats. This indicates that malfunction of medullospinal 5-HT neurons
may be an important contributor to the development of chronic pain in peripheral
neuropathies. Furthermore, this suggests that S2 stimulation acts by reversing CeA-
driven pronociceptive activation of medullospinal 5-HT neurons. Other mechanisms
for S2 stimulation-induced pain attenuation include antinociceptive changes in
Results and discussion
44





Although intracranial cannulae targeted the CeA (I, II, IV), the volume of injections
was large enough (0.5 μl) for drugs to spread to adjacent brain structures, including
other amygdaloid nuclei. Therefore, the action of drugs on neurons outside the CeA
may have interfered with our results. On the other hand, the CeA acts as the output
nucleus of the amygdala with regard to pain modulation. Furthermore, injection of
drugs into a control site (internal capsule) failed to produce any alterations in pain
behavior. Taken together, this indicates that changes in pain behavior, most likely,
resulted from the action of drugs on neurons in the CeA.
Caution is necessary in comparing the results collected from the different studies in
this thesis. In amygdaloid studies (I, II, IV), we assessed mechanical pain in freely
moving  SNI  rats.  In  the  cortical  study  (III), we assessed heat pain in lightly
anesthetized SNL rats. Such inconsistency in experimental settings may have
introduced bias to our results, which demonstrate overlap in mechanisms for pain
regulation by the amygdala (i.e., CeA) and the cortex (i.e., S2). Furthermore, not all
aspects of pain were assessed. In studies II and IV, we assessed sensory-
discriminative and affective-motivational aspects of pain, whereas in studies I and
III, we assessed only the former. We also did not assess ongoing pain in any of the
studies, although ongoing pain represents a major complaint among neuropathic
patients.
We inhibited medullospinal 5-HT neurons by activating 5-HT1A autoreceptors on
their  cell  bodies  with  8-OH-DPAT  injections  into  the  RVM  (I, III). We, however,
cannot exclude that activation of 5-HT1A heteroreceptors on other cells (neural
[142] or glial [5]) influenced our results.
Although previous studies demonstrate that at least some of the ON and OFF cells
in the RVM have spinal projections [40,169], we did not verify that the ON and OFF
cells recorded in our study (III) indeed represented medullospinal neurons.
Furthermore, the RVM can comprise ascending projections from the area around
the central canal of the spinal cord [62]. If these ascending projections contribute to
transmission of nociception, then they may resemble electrophysiologically ON or
OFF cells. Collision testing, for example, could have clarified whether recorded in




We demonstrated that pain-modulating pathways descending from the S2 (III) and
the CeA (I, IV)  merge in the RVM. It  is  therefore possible that  the S2 and the CeA
modulate pain in tandem. Future studies may address whether S2 stimulation
attenuates neuropathic pain by modulating the activity of the CeA or by modulating
the activity of the PAG, which connects the CeA to the RVM.
We also demonstrated that administration of antioxidants or TRPA1 antagonists
into the CeA attenuates neuropathic pain (IV), which is consistent with previous
findings of their antinociceptive properties in the spinal cord [178,180]. From a
clinical perspective, it is therefore of great interest to see if antioxidants and TRPA1
antagonists can attenuate neuropathic pain, when administered systemically, and
to examine whether their action at the spinal or supraspinal level plays a more
important role in attenuation of neuropathic pain. In addition, it is interesting to
see if systemic administration of antioxidants can potentiate antinociceptive action
of S2 stimulation.
A recent clinical study [99] demonstrated that the S2 is an effective cortical
stimulation site for attenuating neuropathic pain with TMS. In line with this, our
study (III) shows that electrical stimulation of the S2 also attenuates neuropathic
pain in rats and reveals the mechanism for S2 stimulation-induced pain attenuation.
It remains to be studied whether a similar mechanism contribute to pain
attenuation induced by TMS of the S2 in neuropathic patients.
Implementation of antidepressants, such as selective serotonin reuptake inhibitors
(SSRI), has produced controversial results in treatment of neuropathic pain (for a
review, see [82]). This is consistent with our findings, which suggest that
medullospinal 5-HT neurons can account for both attenuation (I, III, IV) and
exacerbation (I) of neuropathic pain. Investigation of how various SSRI influence the
activity of medullospinal 5-HT neurons may lead to improved clinical use.
Since electrical stimulation of the S2 (III) and pharmacological inhibition of the CeA
(I, IV) attenuated neuropathic pain by activating spinal 5-HT1A receptors, it may be
expected that spinal administration of a 5-HT1A agonist also attenuates neuropathic
pain. However, since pain attenuation induced by electrical stimulation of the S2
and by pharmacological inhibition of the CeA can be prevented by activation of 5-
HT1A receptors  in  the RVM (I, III),  systemic administration of  a  5-HT1A agonist may
prove inefficacious. In light of this notion, spinal (but not systemic) administration
of  BUSPIRONE  may  serve  as  a  new  method  for  clinical  treatment  of  neuropathic
pain. BUSPIRONE represents one of the few clinically approved drugs that acts as a
5-HT1A receptor agonist. Currently, BUSPIRONE is used to treat anxiety but not
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neuropathic pain, despite the fact that anxiety represents one of the comorbidities
of neuropathic pain. The reason for this lies in inefficacy of BUSPIRONE to attenuate
pain in neuropathic patients when administered systemically [79]. Our studies (I, III,






 NMDA receptors in the CeA maintain its pronociceptive hyperactivity
characterized by activation of spinal 5-HT3 receptors (I).
 Activation of non-NMDA glutamate receptors in the CeA suppresses its
pronociceptive hyperactivity and leads to descending antinociception
mediated by spinal 5-HT1A receptors (I).
 ROS contribute to CeA-driven pain hypersensitivity and pain affect through
activation of TRPA1 and TRPC4/5 channels in the CeA (II, IV).
 Activation of medullospinal 5-HT neurons is necessary for both CeA-induced
facilitation and inhibition of spinal nociception (I, IV).
 S2 stimulation attenuates neuropathic pain by promoting antinociceptive
activity of medullospinal 5-HT neurons and of (presumably medullospinal)
non-5-HT neurons (ON and OFF cells; III).
By summarizing the results of the present studies (I-IV),  the table below (Table 6)
describes the mechanisms of neuropathic pain development and suggests new
approaches to its treatment.
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Table 6. Mechanisms of neuropathic pain development and possible approaches to its treatment.
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